Join
Live feed
·
PRReleasevia Quantisnow
Axsome Therapeutics Inc. logo

Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)

ByQuantisnow·Wall Street's wire, on your screen.
AXSM· Axsome Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AXSM (Axsome Therapeutics Inc.) and more on Quantisnow.